Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB

 Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB
April 24, 2025

Vinge advises Biotage in connection with RWK Bidco’s public tender

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.
April 22, 2025

Vinge advises Baseload Capital in connection with an investment from Google

 Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025